From editing genes to programming living systems
The active flagship topic reads the field as a race to expand what genome editing can do. CRISPR is no longer treated as a single tool, but as the starting point for a family of editors: base editors, prime editors, protein editors, RNA-guided systems and newer mechanisms that promise larger insertions or cleaner control.
The most distinctive through-line is engineering in the body itself. Posts on in vivo T cell reprogramming, CAR-T advances and immune-cell rejuvenation show a steady interest in moving from laboratory manipulation to programmable therapeutic systems inside patients.
Disease stories matter here, but they are usually read through the machinery that makes treatment possible. Huntington’s disease, progeria, alternating hemiplegia and solid tumors appear as tests of delivery, specificity, durability and safety rather than as isolated headlines.
- Further reading
- In Vivo Base Editing Partially Rescues Bone Dysplasia in a Mouse Model of Hutchinson‐Gilford Progeria Syndrome - PMC
- Protein-templated synthesis of dinucleotide repeat DNA by an antiphage reverse transcriptase - Science
- Engineered CAR T cells show promise against solid tumors
- New generation of CRISPR shows safer path to treating genetic diseases
- Huntington’s disease treated for first time using gene therapy - Nature